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Abstract
In 2016, the global health sector strategy (GHSS) on viral hepatitis called for elimination 
of hepatitis B as a major public health threat by 2030 (i.e., 90% reduction in incidence and 
65% in mortality). But persistence or clearance of hepatitis B virus (HBV) infection mainly 
depends upon host immune responses. The human leukocyte antigen (HLA) system is 
the center of host immune responses. HLA genes are located in chromosome 6p21.31 
and cover 0.13% of the human genome and show a high degree of polymorphism and 
extensive patterns of linkage disequilibrium (LD), which differ among populations. The 
HLA genes include HLA class I, HLA class II, and other non-HLA alleles. HLA class 
II gene polymorphisms are strongly associated with not only persistent HBV infection 
but also spontaneous HBV clearance and seroconversion, disease progression, and the 
development of liver cirrhosis (LC) and HBV-related hepatocellular carcinoma (HCC) in 
chronic hepatitis B. This chapter summarizes the reported associations of HLA class II 
gene polymorphisms with the outcomes of HBV infection and their related mechanisms.
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1. Introduction
Since the discovery of hepatitis B virus (HBV) by Blumberg et al. in 1965, much has been elu-
cidated regarding its virion, infection, prevention, and treatment [1, 2]. However, HBV infec-
tion continues to be a significant public health problem that has not yet been fully addressed 
worldwide [3, 4].
HBV infection is caused by HBV, an enveloped DNA virus that infects the liver causing 
hepatocellular inflammation and necrosis. HBV infection can be either acute or chronic, and 
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the associated illness ranges in severity from asymptomatic to symptomatic and progressive 
disease. Chronic hepatitis B (CHB) is defined as persistence of hepatitis B surface antigen 
(HBsAg) for 6 months or more [2]. The World Health Organization (WHO) reports that 
80–90% of infants infected during the first year of life and 30–50% of children infected before 
the age of 6 years develop chronic infections; less than 5% of otherwise healthy persons who 
are infected as adults will develop chronic infection; and 20–30% of adults who are chroni-
cally infected will develop cirrhosis and/or liver cancer [4]. In 2015, 257 million people lived 
with HBV infection defined as hepatitis B surface antigen positive; and hepatitis B resulted in 
887,000 deaths, mostly from complications including liver cirrhosis (LC) and hepatocellular 
carcinoma (HCC) [4]. Once infected with HBV, one of the main risks is the development of 
cirrhosis, hepatic decompensation, and ultimately HCC [2–6]. In 2016, the global health sector 
strategy (GHSS) on viral hepatitis called for elimination of viral hepatitis as a major public 
health threat by 2030 (i.e., 90% reduction in incidence and 65% in mortality) [5]. In 2017, 
WHO’s first-ever Global hepatitis report presented the baseline values for each of the core 
indicators of the strategy [6].
The prevention component of elimination is on track with respect to hepatitis B vaccination, 
blood safety, and injection safety [7–10]. A promising but limited start in hepatitis testing 
and treatment needs to be followed by immediate and sustained action so that we reach the 
service coverage targets required to achieve elimination by 2030 [3]. Levrero et al. [11], Vyas 
et al. [12], and Yoo et al. [13] reviewed that multiple emerging drug therapies are currently in 
the early stages of development as part of the growing effort to find a true cure for HBV. But 
persistence or clearance of HBV infection mainly depends upon host immune responses.
The major histocompatibility complex (MHC) was discovered in the mouse in 1936 [14]. 
The human leukocyte antigen (HLA) system, MHC in humans, is the center of host immune 
responses [15–17]. HLA genes are located in chromosome 6p21.31 [18] and cover 0.13% of the 
human genome [19] and show a high degree of polymorphism and extensive patterns of link-
age disequilibrium (LD), which differ among populations. The HLA genes include HLA class I, 
HLA class II, and other non-HLA alleles [20]. HLA class I alleles include the three classic HLA 
gene loci: HLA-A, HLA-B, and HLA-C; three non-classic HLA-E, HLA-F, and HLA-G gene 
loci, which show limited polymorphism compared to the classic class I loci; and other related 
non-coding genes and pseudogenes [20]. The main function of HLA class I molecules, which 
are expressed in all nucleated cells, is to present non-self antigens derived from intracellular 
sources, such as viruses, to CD8+ T cells (cytotoxic T cells, CTL), which then identify and kill 
infected cells [21]. CD8+ T cells interact with the cognate peptide-MHC I complexes via their 
T-cell receptor (TCR) and co-receptor molecule CD8. HLA class II alleles include the classic 
gene loci HLA-DR, HLA-DQ, and HLA-DP and also the non-classic HLA-DO and HLA-DM 
loci [20]. The classic genes are expressed on the surface of professional antigen-presenting 
cells (APCs), which take up antigens derived from extracellular sources [22], such as bacteria 
or food, and present them to CD4+ T helper cells. This leads to the secretion of various small 
proteins, including cytokines, which regulate other immune cells such as macrophages or B 
cells. In turn, macrophages can destroy ingested microbes, and activated B cells can secrete 
antibodies. CD4+ T cells interact with the cognate peptide-MHC II complexes via their TCR 
and the co-receptor molecule CD4. Non-classic molecules are exposed in internal membranes 
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in lysosomes, which help load antigenic peptides on to classic MHC class II molecules. Over 
the past 50 years, polymorphisms in the HLA locus have been shown to influence many criti-
cal biological traits and individuals’ susceptibility to complex, autoimmune, and infectious 
diseases [17, 23, 24]. Since 1979, Kew et al. [25] started the research for the association between 
histocompatibility antigens and HBV infection, and a plenty of researches demonstrated that 
the highly polymorphic HLA classes I and II genes can affect the ability of HLA molecules 
to trigger immune responses, which affects the outcomes of HBV infection, and discrepant 
conclusions were reached in different cohorts [26, 27]. HLA class II gene polymorphisms are 
strongly associated with not only persistent HBV infection but also spontaneous HBV clear-
ance and seroconversion, disease progression, and the development of LC and HBV-related 
HCC in chronic hepatitis B [28–30]. This chapter summarizes the reported associations of 
HLA class II gene polymorphisms with susceptibility to HBV infection, resolution, and dis-
ease progression and their related mechanisms.
2. HLA class II gene and the clinical outcomes of HBV infection
HLA class II gene includes HLA-DRA
1
, -DRB
1~9
, -DQA
1
, -DQB
1
, -DPA
1
, -DPA
2
, -DPB
1
, -DPB
2
, 
-DOA, -DOB, -DMA, and -DMB with 4857 alleles known with the latest report update on 
April 16, 2018 (http://www.ebi.ac.uk/imgt/hla/stats.html). HLA-DRB1 has the most allelic 
variability with 2165 alleles, and in turn HLA-DQB1 with 1196 alleles, HLA-DPB1 with 975 
alleles, and HLA-DRB3 with 157 alleles [20].
2.1. HLA class II allele polymorphism and HBV infection outcomes
HLA-DR is widely used in transplant gene matching [31] and as an activated T cell surface 
marker [32], and early related to the clinical outcomes of HBV infection [33]. In 2013, we 
reviewed the relationship between HLA class II alleles and HBV infection, there are the most 
number of HLA-DR alleles relatived to HBV infection, such as HLA-DRB
1
*03, 07, 09 and 12, 
may be the risk factors of HBV infection; and HLA-DRB
1
*04, 11, 13 and 14 may be the protect 
factors of HBV infection [26]. In 2016, Wang et al. also reviewed the relationship of HLA-DR 
alleles with HBV infection [27], including HLA-DRB
1
*1301-02 which is consistently associated 
with HBV clearance globally, such as in Gambia, Germany, Korea, and Spain; HLA-DRB
1
*11 
and -DRB
1
*14 are associated with spontaneous recovery in patients with HBV subgenotype 
C2 infection in Northeast China; HLA-DR
2
, HLA-DR*0406, and HLA-DR
7
 antigens are associ-
ated with protective effect on acute HBV infection; and HLA-DRB
1
*08 and -DRB
1
*09 alleles, 
which are susceptible to HBV infection, were found in Brazilian populations determined in 
young and male blood donors. Meanwhile, HLA-DRB
1
*11/12 alleles are associated with HBV 
persistence globally, and HLA-DRB
1
*07 is the only one associated with infant susceptibility 
to intrauterine HBV infection and a significant negative predictor of cirrhosis. Our researches 
also showed that: -DRB
1
*13 may protect subjects from HBV infection [26]; -DRB
1
*12 may have 
a high risk for HBV infection [26]; and -DRB
1
*07 and 12 may be implied in viral persistence 
[26, 34]. Analysis still identified HLA-DRB
1
*12:02 as the top susceptible HLA allele associ-
ated with acute-on-chronic liver failure (ACLF) [35]. A large number of studies have been 
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conducted to identify HLA-DRB1 genetic variants associated with HCC risk and clinical out-
comes, but many of the findings in these studies are inconsistent and inconclusive [36–38]. 
A meta-analysis by Lin et al. reported an ethnicity-dependent association between specific 
HLA-DRB1 alleles and HCC risk, DRB
1
*07 and DRB
1
*12 were significantly associated with 
the risk of HCC in the whole populations, and DRB
1
*15 allele significantly increased the 
risk of hepatocellular carcinoma only in Asians [36]. One research by Ma et al. suggests that 
if genetic factors play a role in familial aggregation of hepatocellular carcinoma, the defi-
ciency in the DRB
1
*11 and DRB
1
*12 alleles might be the risk factor at work in the Guangxi 
Zhuang Autonomous Region, P.R.C. [37]. Another meta-analysis by Liu et al. reported that 
HLA-DRB
1
*01 and 11 alleles were protective factors, while HLA-DRB
1
*12 and 14 alleles were 
risk factors for HCC development [38]. These findings are somewhat reasonable considering 
the incidence and distribution of HCC which are closely linked to environmental, dietary, 
and lifestyle factors, as well as genetic profiles, but the risk for HCC was not controlled for 
possible confounders such as HBV or HCV, which are more prone to bias than that of the 
randomized clinical trial studies.
HLA-DQ belongs to one of HLA class II molecules; it is also expressed as cell-surface glycopro-
teins that bind to exogenous antigens and present them to CD4+ T cells. HLA-DQ molecules 
function as a heterodimer of alpha and beta subunits which are encoded by the HLA-DQA
1
 
and HLA-DQB
1
 genes, respectively. HLA-DQs are highly polymorphic especially in exon 2 
which encode antigen-binding sites. Therefore, a number of alleles have been declared to 
be associated with persistent HBV infection [26, 27]—HLA-DQA
1
*0102, 0201, 0301, and 0402 
and HLA-DQB
1
*0604, and so on associated with HBV clearance; and HLA-DQA
1
*0103, 0201, 
0302, and 0501 and HLA DQB
1
*0301, and so on associated with HBV persistence [26]; the two-
locus haplotype consisting of -DQA
1
*0501 and -DQB
1
*0301, and the three-locus haplotype 
consisting of -DQA
1
*0501, -DQB
1
*0301, and -DRB
1
*1102 were significantly associated with 
persistent HBV infection in an African-American cohort; -DQB
1
*0301 was associated with 
HBV persistence globally; in addition, -DQB
1
*0201 is a HBV-resistant gene, and -DQB
1
*0303 
is a susceptibility gene of carrying HBV in Xinjiang Uygur ethnic groups of China; and 
-DQB
1
*0503 are associated with early HBeAg seroconversion in CHB children in Taiwan [27]. 
HLA genotyping-based analysis identified -DQB
1
*0601 as having the strongest association, 
showing a greater association with CHB susceptibility [28].
The HLA DPA
1
 and HLA DPB
1
 belong to the HLA class II alpha and beta chain paralogs, 
which also make a heterodimer consisting of an alpha and a beta chain on the surface of 
antigen-presenting cells. This HLA class II molecule also plays a central role in the immune 
system by presenting peptides derived from extracellular proteins. Identification of a total 
of five alleles, including two risk alleles (DPB
1
*09:01 and DPB
1
*05:01) and three protective 
alleles (DPB
1
*04:01, DPB
1
*04:02, and DPB
1
*02:01), would enable HBV-infected individuals 
to be classified into groups according to the treatment requirements. Moreover, among the 
five reported HLA-DPB
1
 susceptibility alleles, three DPB
1
 alleles (DPB
1
*05:01, *02:01, and 
*04:02) had primary effects on CHB susceptibility. However, the association of the remaining 
two alleles (DPB
1
*09:01 and *04:01) had come from LD with HLA-DR-DQ haplotypes (i.e., 
DRB
1
*15:02-DQB
1
*06:01 and DRB
1
*13:02-DQB
1
*06:04, respectively) [28, 39].
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2.2. Single nucleotide polymorphisms at HLA class II gene and HBV infection 
outcomes
HLA gene variations are strongly associated with HBV infection outcomes in not only HLA 
alleles but also single nucleotide polymorphisms (SNPs) identified through genome-wide 
associated studies (GWASs). Recent GWASs have revealed several SNPs at HLA class II 
region associated with the risk of HBV infection [23, 30].
A Chinese study by Zhu et al. [40] identified two HLA-DR loci that independently drive 
chronic HBV infection, including HLA-DRβ113 sites 71 and rs400488. Acute-on-chronic liver 
failure (ACLF) is an extreme condition after severe acute exacerbation of chronic hepatitis 
B. Tan et al. carried out a genome-wide association study, among 1300 ACLFs and 2087 AsCs, 
and identified rs3129859 at HLA class II region (chromosome 6p21.32) which is associated 
with HBV-related ACLF. Analysis identified HLA-DRB
1
*12:02 as the top susceptible HLA 
allele associated with ACLF. The association of rs3129859 was robust in ACLF subgroups 
or HBV e antigen-negative chronic hepatitis B phase. Clinical traits analysis in patients with 
ACLF showed that the risky rs3129859*C allele was also associated with prolonged pro-
thrombin time, faster progression to ascites development, and higher 28-day mortality [35]. 
SNP rs9272105 locates between HLA-DQA
1
 and HLA-DRB
1
 on 6p21.32. SNP imputation in 
the GWAS discovery samples revealed additional SNPs showing association, but rs9272105 
remained the top SNP within the region [41], which successfully validated the associations 
between rs9272105 and HCC risk [42]. Of the 12 SNPs reported in HBV-related HCC GWASs, 
rs2647073 and rs3997872 near HLA-DRB1 were found to be significantly associated with the 
risk of HBV-related LC, which suggested that genetic variants associated with HBV-related 
hepatocarcinogenesis may already play an important role in the progression from CHB to 
LC [43]. A recent study reported new SNPs at HLA-DRB
1
 (rs35445101) associated with TP53 
expression status in HBV-related hepatocellular carcinoma [30].
In 2013, Jiang et al. first found the association of HCC risk with rs9275319 at 6p21.3 located 
between HLA-DQB
1
 and HLA-DQA
2
, which was not reported in earlier GWASs of HCC [44]. 
Their following research and that of Wen et al. successfully validated the associations between 
rs9275319 and HCC risk [42, 43]. Three SNPs belonging to the HLA-DQ region (rs2856718, 
rs7453920, and rs9275572) were studied. HLA-DQ rs2856718G, rs7453920A, and rs9275572A 
were strongly associated with decreased risk of chronic HBV infection and natural clearance; 
while rs2856718A, rs7453920G, and rs9275572G served as a risk factor in HBV infection in 
Japanese populations and in Southeast China [45–48]. Chang et al. found that rs9276370 
(HLA-DQA
2
), rs7756516, and rs7453920 (HLA-DQB
2
) are significantly associated with persis-
tent HBV infection, especially the “T-T” haplotype composed of rs7756516 and rs9276370 that 
is more prevalent in severe disease subgroups and associated with nonsustained therapeutic 
response in male Taiwan Han Chinese individuals [49]. A nearest study reported four new 
SNPs at HLA-DQB
1
 (rs1130399, rs1049056, rs1049059, and rs1049060) associated with TP53 
expression status in HBV-related HCC [30].
A Chinese study by Zhu et al. [40] identified HLA-DPβ
1
 positions 84–87 that indepen-
dently drive chronic HBV infection. In 2009, Kamatani et al. first reported two SNPs with 
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the strongest relation to HBV infection from the HLA-DP locus: rs3077 on HLA DPA1 and 
rs9277535 on HLA DPB
1
 in Japanese and Thai populations [50, 51]. Subsequently, plenty of 
studies further demonstrated their roles [27, 52–54]. rs3077 and rs9277535 are significantly 
related to HBV persistent infection and both A alleles of these two SNPs are protection alleles 
in Chinese Han [55], Japanese and Korean [56], and European [57] populations, while in 
Chinese Zhuang subjects, only HLA-DP rs9277535A is associated with decreased risk [55]. 
Also, only a highly significant association of HLA-DPA
1
 rs3077C with HBV infection was 
observed in Caucasians [58]. HBeAg-negative HBV carriers with rs9277535 non-GG genotype 
had a higher chance to clear HBsAg. Compared to GG haplotype of rs3077 and rs9277535, 
GA haplotype had a higher chance of achieving spontaneous HBsAg loss in Chinese subjects 
of Taiwan [59]. On the whole, the present findings show that SNPs rs3077 and rs9277535 at 
HLA-DP locus protect against HBV infection and increase the chance of HBV clearance, while 
the importance of these polymorphisms as a predictor of HCC may be limited [45, 60, 61]. In a 
report by Hu et al., HLA-DP rs3077 showed an approaching significant effect on susceptibility 
to HBV persistent infection and HCC development when considering multiple testing adjust-
ments [62]. Li et al. found evidence for the association at rs9277535 with HCC independently 
by imputation [41]. Thomas et al. reported that SNPs rs3077 and rs9277535 that associated 
most significantly with chronic hepatitis B and outcomes of HBV infection in Asians had a 
marginal effect on HBV recovery in European and African-American samples. However, they 
identified a novel variant in the HLA-DPB
1
 3′UTR region, 496A/G (rs9277534), which associ-
ated very significantly with HBV recovery in both European and African-American popula-
tions [63]. Hu et al. also found that the variant at rs9277534 could affect both the spontaneous 
clearance of HBV infection and progression from asymptomatic HBV carriers to HBV-related 
liver cirrhosis in southwest Han Chinese population [64]. Chang et al. found that rs9366816 
near HLA-DPA3 are significantly associated with persistent HBV infection in male Taiwan 
Han Chinese individuals [49]. A nearest study reported a new SNP at HLA-DPB1 (rs1042153) 
associated with TP53 expression status in HBV-related hepatocellular carcinoma [30].
2.3. The role and mechanism of HLA class II gene variations associated with HBV 
infection outcomes
HLA class II genes encode proteins expressed on the surface of antigen-presenting cells such 
as macrophages, dendritic cells, and B cells, and thereby have a critical role in the presenta-
tion of antigens to CD4+ T-helper lymphocytes. In our previous review, there were three 
mechanisms related to HBV infection outcomes, including HLA molecular structure, HLA 
gene expression, and its regulatory [26].
HLA class II genes have many structural variants that have been linked to immune response 
[65, 66] to autoimmune diseases [67, 68], idiosyncratic drug toxicity (IDT) [69, 70], and infectious 
agents [71, 72]. But the structural variants related to HBV infection outcomes in HLA class II 
genes only have our previous research report [73]. We know that the HLA class II molecules are 
heterodimetric glycoproteins, which are able to present peptides to CD4+ T cells; the primary 
protein sequences (α1 and β1 chains) encoded by the second exon of the HLA class II genes com-
prise the peptide-binding grooves that accommodate amino acid chains of the bound peptides; 
the specificity of the peptide-binding grooves is governed by the properties of pockets in the 
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grooves which include nine different structural pockets (Ps) from P1 to P9, typical pockets being 
P1, P4, P6, and P9, which accommodate the antigen peptide side chains; and the polymorphic 
residues encoded by polymorphic HLA class II genes can influence the structural (size and 
shape) and electrostatic properties and further function of the pockets. So, the determination of 
the structural and electrostatic properties of the HLA class II peptide-binding grooves associ-
ated with diseases may help identify the disease mechanism. We found that DR07 and DR12 
carry amino acids Leu and His at residue 30 of HLA-DRβ1 chain, respectively, and Val at residue 
57 of HLA-DRβ1 chain, difference from Tyr30 and Asp57 carried by DR04 and DR11, leading to 
present positive charge at P9 [73], as well as increasing size due to the absence of an intact salt 
bridge at P6 and P9 [73, 74]. Hence, which HLA DR07 and DR12 is sufficient to chronic HBV 
infection is supported by the structure characters resulting from HLA gene polymorphism.
Gene expression, that is, the qualitative and quantitative expression of mRNA transcripts 
from DNA templates, forms a first link in the functional path between nucleotide sequence 
and higher-order organismal phenotypes. Despite the undeniable importance of a controlled 
gene regulatory process in which proper transcripts are expressed at the correct time and 
location, studies have shown that there is widespread inter-individual variability with respect 
to gene expression, or mRNA levels, within a given cell type or tissue [75]. Early in 1986, 
Edwards et al. [76] examined frozen sections of human fetal spleen from 12 to 20 weeks of 
gestation by using polyclonal antibodies to Ig isotypes, monoclonal antibodies to HLA class II 
subregion locus products, B and T cells, and follicular dendritic cells. Their data suggest that 
class II antigens are differentially expressed on developing lymphoid cells; DR and DP expres-
sion occurring in the earliest spleens examined, with expression of DP on a subpopulation of 
DR-positive cells; IgD and DQ expression appears to be coincident on maturing B cells as they 
begin to form follicles, and an immunoregulatory role for HLA-DQ in B cell development is 
implicated. In fact, HLA class II gene (HLA-DR) expression level is still one of the markers for 
immune reaction related to disease [33, 77]. In 2017, we reviewed the association of HLA-DR 
expression level with diseases and reported our studies about the characteristics of HLA-DR 
expression in patients with different outcomes of HBV infection. Compared to persons with 
no HBV marker, HBV infection and vaccination induce increased expression of HLA-DR, 
especially in the clearance of HBV infection [78]. Genetic variants that influence HLA mRNA 
expression might also affect antigen presentation and many “gene expression-associated 
SNPs” (eSNPs) have been found for HLA genes [79, 80]. An integrated approach combining 
genotype information with genome-wide gene expression data in relevant tissues can identify 
genetic variations that are both regulatory and disease causing [81]. Cavalli et al. believed that 
a majority of causal genetic variants underlying complex diseases appear to involve regu-
latory elements, rather than coding variations [82]. Kaur et al. reported that structural and 
regulatory diversity shape HLA-C protein expression levels and that quantitative variation 
in the expression of HLA-C can influence the clinical course of HIV infection and the risk of 
graft-versus-host disease [83]. By influencing HLA mRNA expression, rs3077 and rs9277535 
variants, both are noncoding variation (3′UTR) in the HLA-DPA
1
 and HLA-DPB
1
 region, and 
are related to enhanced clearance of hepatitis B virus infection [57, 63] and increased risk 
of graft-versus-host disease in mismatched hematopoietic cell transplant recipients [84, 85]. 
These findings were identified by a study about mapping of hepatic expression quantitative 
trait loci (eQTLs) in a Han Chinese population by Wang et al. [86].
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eQTLs, namely, the discovery of genetic variants, explain variation in gene expression levels 
which has significant differences in mean expression levels between population, tissue or cell 
type [75, 87]. Typically, in the eQTL mapping literature, regulatory variants have been charac-
terized as either cis or trans acting, reflecting the predicted nature of interactions and of course 
depending on the physical distance from the gene they regulate. Conventionally, variants within 
1–2 Mb (megabase) on either side of a gene’s TSS were called cis, while those at least 5 Mb 
downstream or upstream of the TSS or on a different chromosome were considered trans act-
ing [87]. The most significant GWAS SNPs are strong eQTLs and proposing candidate disease 
genes. Multiple variants of low-effect sizes affect multiple genes by gene regulatory network. 
A network component can be viewed as a cis effect that transmits its signal in trans essentially 
making the cis SNP a trans SNP as well [87]. Such studies have offered promise not just for 
the characterization of functional sequence variation but also for the understanding of basic 
processes of gene regulation and interpretation of genome-wide association studies [75, 87].
Up to now, many research findings have demonstrated that HLA class II gene variations, 
including allele polymorphisms and SNPs, are associated with HBV infection outcomes 
by influencing the molecular structure and the expression level of HLA class II molecules 
expressed on the cell surface. As the researches progress with methodological improvements, 
such as the prediction of gene expression [88] and PrediXcan analysis [89], more structure 
variations, cis SNPs and trans SNPs, were found underlying this disease. This can help under-
stand the mechanisms linking genome-wide association loci to the disease, and implement 
precise individualized prevention, diagnosis, and treatment of the disease.
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